Literature DB >> 33468188

Hepatitis C virus cascade of care in the general population, in people with diabetes, and in substance use disorder patients.

Olivera Djuric1,2, Marco Massari3, Marta Ottone4, Giorgia Collini4, Pamela Mancuso4, Massimo Vicentini4, Antonio Nicolaci5, Angela Zannini5, Alessandro Zerbini6, Valeria Manicardi7, Loreta A Kondili8, Paolo Giorgi Rossi4.   

Abstract

BACKGROUND: The aim was to evaluate the hepatitis C virus (HCV) cascade of care in the general population (GP) and in two high-risk populations: patients with diabetes mellitus (DM) and substance users (AS) in treatment in Reggio Emilia Province, Italy.
METHODS: A population-based cross-sectional study was conducted that included 534,476 residents of the Reggio Emilia Province, of whom 32,800 were DM patients and 2726 AS patients. Age-adjusted prevalence was calculated using the direct method of adjustment based on the age-specific structure of EU population.
RESULTS: The prevalence of HCV testing was 11.5%, 13.8%, and 47.8% in GP, DM, and AS patients respectively, while HCV prevalence was 6.5/1000, 12.6/1000, and 167/1000, respectively. The prevalence of HCV RNA positivity was 4.4/1000, 8.7/1000, and 114/1000 in the three populations, respectively. The rates of HCV RNA-positive individuals not linked to care were 27.9%, 27.3%, and 26% in GP, DM, and AS patients, respectively, while the rates of those cured or cleared were 70.9%, 71%, and 69.9%, respectively. The prevalence of HCV testing was higher for females of reproductive age than for males the same age: 218.4/1000 vs. 74.0/1000, respectively. While more foreigners than Italians underwent the HCV test and were HCV positive, fewer foreigners than Italians received HCV treatment and were cured.
CONCLUSIONS: The low HCV testing and linkage to care rates remain an important gap in the HCV cascade of care in Northern Italy. The prevalence of cured/cleared residents remains lower among foreigners than among Italians.

Entities:  

Keywords:  Addiction; Cascade of care; Diabetes mellitus; Hepatitis C virus; Hepatocellular carcinoma; Linkage to care

Year:  2021        PMID: 33468188      PMCID: PMC7816419          DOI: 10.1186/s13027-021-00345-8

Source DB:  PubMed          Journal:  Infect Agent Cancer        ISSN: 1750-9378            Impact factor:   2.965


  42 in total

1.  Risk of cancer in individuals with alcohol and drug use disorders: a registry-based study in Reggio Emilia, Italy.

Authors:  Pamela Mancuso; Olivera Djuric; Giorgia Collini; Emanuela Serventi; Marco Massari; Alessandro Zerbini; Paolo Giorgi Rossi; Massimo Vicentini
Journal:  Eur J Cancer Prev       Date:  2020-05       Impact factor: 2.497

2.  Barriers to effective management of hepatitis C virus in people who inject drugs: Evidence from outpatient clinics.

Authors:  Sabrina Molinaro; Giuliano Resce; Alfredo Alberti; Massimo Andreoni; Pietro P F D Egidio; Claudio Leonardi; Felice A Nava; Patrizio Pasqualetti; Stefano Villa
Journal:  Drug Alcohol Rev       Date:  2019-08-23

3.  Seroprevalence of hepatitis C in type 2 diabetes: evidence for a positive association.

Authors:  Nauman A Jadoon; Mohammad A Shahzad; Rehan Yaqoob; Mansoor Hussain; Naseema Ali
Journal:  Virol J       Date:  2010-11-05       Impact factor: 4.099

4.  Test uptake and hepatitis C prevalence in 5483 Danish people in drug use treatment from 1996 to 2015: a registry-based cohort study.

Authors:  Anne Øvrehus; Stine Nielsen; Janne Fuglsang Hansen; Dorte Kinggaard Holm; Peer Christensen
Journal:  Addiction       Date:  2018-11-25       Impact factor: 6.526

5.  Association of diabetes mellitus and chronic hepatitis C virus infection.

Authors:  A L Mason; J Y Lau; N Hoang; K Qian; G J Alexander; L Xu; L Guo; S Jacob; F G Regenstein; R Zimmerman; J E Everhart; C Wasserfall; N K Maclaren; R P Perrillo
Journal:  Hepatology       Date:  1999-02       Impact factor: 17.425

6.  Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: evidence for a vanishing infection.

Authors:  Vincenzo Guadagnino; Tommaso Stroffolini; Benedetto Caroleo; Francesca Menniti Ippolito; Maria Rapicetta; Anna Rita Ciccaglione; Paola Chionne; Elisabetta Madonna; Angela Costantino; Giovambattista De Sarro; Alfredo Focà; Margherita Lentini; Orietta Staltari
Journal:  Dig Liver Dis       Date:  2012-11-28       Impact factor: 4.088

7.  Seroprevalence of Hepatitis B and C Viral Infections among Type 2 Diabetics: A Cross-sectional Study in the Cape Coast Metropolis.

Authors:  Rkd Ephraim; P Nsiah; Dnm Osakunor; P Adoba; Sa Sakyi; Eo Anto
Journal:  Ann Med Health Sci Res       Date:  2014-09

Review 8.  Type 2 diabetes mellitus and the risk of hepatitis C virus infection: a systematic review.

Authors:  Xuan Guo; Min Jin; Ming Yang; Ke Liu; Jun-wen Li
Journal:  Sci Rep       Date:  2013-10-18       Impact factor: 4.379

9.  Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

Authors:  Loreta A Kondili; Sarah Robbins; Sarah Blach; Ivane Gamkrelidze; Anna L Zignego; Maurizia R Brunetto; Giovanni Raimondo; Gloria Taliani; Andrea Iannone; Francesco P Russo; Teresa A Santantonio; Massimo Zuin; Luchino Chessa; Pierluigi Blanc; Massimo Puoti; Maria Vinci; Elke M Erne; Mario Strazzabosco; Marco Massari; Pietro Lampertico; Maria G Rumi; Alessandro Federico; Alessandra Orlandini; Alessia Ciancio; Guglielmo Borgia; Pietro Andreone; Nicola Caporaso; Marcello Persico; Donatella Ieluzzi; Salvatore Madonia; Andrea Gori; Antonio Gasbarrini; Carmine Coppola; Giuseppina Brancaccio; Angelo Andriulli; Maria G Quaranta; Simona Montilla; Homie Razavi; Mario Melazzini; Stefano Vella; Antonio Craxì
Journal:  Liver Int       Date:  2018-08-10       Impact factor: 5.828

Review 10.  Epidemiology and Elimination of HCV-Related Liver Disease.

Authors:  Pierre Pradat; Victor Virlogeux; Eric Trépo
Journal:  Viruses       Date:  2018-10-06       Impact factor: 5.048

View more
  1 in total

1.  Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation.

Authors:  Andrea Marcellusi; Francesco Saverio Mennini; Murad Ruf; Claudio Galli; Alessio Aghemo; Maurizia R Brunetto; Sergio Babudieri; Antonio Craxi; Massimo Andreoni; Loreta A Kondili
Journal:  Liver Int       Date:  2021-10-08       Impact factor: 8.754

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.